title: Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells.
abstract: The role of natural killer T (NKT) cells in the immune response to tumor cells has been largely unexplored. As a model of adoptive tumor immunotherapy, cells from the draining lymph nodes of mice immunized with a tumor-specific or irrelevant antigen were transferred to naïve recipients with established tumor. Inhibition of early tumor growth (day 4) required the transfer of both CD8(+) and J alpha 18(+) (NKT) cells from immunized animals without regard to immunogen. In contrast, CD8(+) cells, but not J alpha 18(+) cells, were necessary for the inhibition of late tumor growth (day 8). Thus, the developing tumor changes in sensitivity to NKT-mediated events and the role for NKT cells cannot be replaced by the presence of tumor-specific cells during early tumor growth. This suggests that recruitment/activation of J alpha 18(+) NKT cells is an important consideration during the immune therapy of early stage tumors.
authors.affiliation: Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, 4102, Australia.
authors.forename: Trina J
authors.initials: TJ
authors.lastname: Stewart
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Smyth
authors.forename: Germain J P
authors.initials: GJ
authors.lastname: Fernando
authors.forename: Ian H
authors.initials: IH
authors.lastname: Frazer
authors.forename: Graham R
authors.initials: GR
authors.lastname: Leggatt
mesh_terms: D000818:Animals; D017951:Antigen Presentation; D018949:Antigens, CD1 / Q000276:immunology; D055610:Antigens, CD1d; D000951:Antigens, Neoplasm / Q000008:administration & dosage / Q000276:immunology*; D016827:CD8 Antigens / Q000032:analysis; D018414:CD8-Positive T-Lymphocytes / Q000737:chemistry / Q000276:immunology* / Q000637:transplantation; D002472:Cell Transformation, Viral / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D018450:Disease Progression; D005260:Female; D015332:Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor; D006017:Glycolipids / Q000276:immunology; D007114:Immunization; D016219:Immunotherapy, Adoptive; D007694:Killer Cells, Natural / Q000737:chemistry / Q000145:classification / Q000276:immunology* / Q000637:transplantation; D051379:Mice; D008810:Mice, Inbred C57BL; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D009856:Oncogene Proteins, Viral / Q000008:administration & dosage / Q000276:immunology*; D050725:Papillomavirus E7 Proteins; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000032:analysis* / Q000235:genetics; D016176:T-Lymphocyte Subsets / Q000737:chemistry / Q000276:immunology* / Q000637:transplantation; D013997:Time Factors; D019139:Tumor Escape / Q000276:immunology
chemical_list: D018949:Antigens, CD1; D055610:Antigens, CD1d; D000951:Antigens, Neoplasm; D016827:CD8 Antigens; D006017:Glycolipids; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D016693:Receptors, Antigen, T-Cell, alpha-beta; C059731:oncogene protein E7, Human papillomavirus type 16